KHB(SZ:002022)2024-03-25 10:27Company Overview - Shanghai Kehua Bio-engineering Co., Ltd. was established in 1981 and is the first IVD listed company on the Shenzhen Stock Exchange [2] - The company specializes in the R&D, production, and sales of in vitro diagnostic reagents and medical testing instruments, covering molecular diagnostics, biochemical diagnostics, immunodiagnostics, and point-of-care testing (POCT) [2][3] - Kehua Bio has approximately 850 domestic and international registrations/certifications for its products, making it one of the most comprehensive companies in the IVD industry [2] Market Presence - The company has a coverage rate of about 60% in tertiary hospitals and 40% in blood stations in China, with nearly 900 clients in disease control centers and thousands of long-term partnerships with domestic and international agents [3] - Products have been exported to over 100 countries and regions worldwide [3][4] Sales Strategy - The sales model combines "mainly distribution, supplemented by direct sales," leveraging a broad network of distributors and a professional marketing team [3] - The company collaborates with various imported brands to provide comprehensive IVD products and services [3] Product Development and Market Strategy - Kehua Bio is actively adjusting its product strategy to cover multiple methodologies, including biochemical, immunofluorescence, molecular, and mass spectrometry [3][4] - The company aims to establish local service teams in key overseas markets, enhancing its global presence and brand recognition [4][5] Share Buyback Program - The company announced a share buyback plan on October 30, 2023, with a total fund of no less than RMB 100 million and no more than RMB 200 million, at a price not exceeding RMB 11 per share [4] - As of February 29, 2024, the company had repurchased 7,357,900 shares, accounting for 1.43% of the total share capital, with a transaction amount of RMB 60,036,310.16 [4] Future Development and Challenges - The company plans to focus on the animal market, including economic and pet animals, with a comprehensive solution covering biochemical, immunological, molecular, and coagulation methodologies [5] - In response to industry competition and trends such as centralized procurement and domestic substitution, the company aims to enhance its market influence and expand its market share [5]